Study glucose changes during steroid and asparaginase treatment
Part of Blood & lymphatic, Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study looks at how blood sugar changes in children and teens receiving treatment for ALL (a leukemia) or lymphoma. It focuses specifically on effects that may be caused by steroids and a medicine called PEG-asparaginase.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a child or teen diagnosed with ALL or lymphoma
- Be receiving standard, approved treatment for ALL or lymphoma in Denmark
- Your treatment plan must match the Denmark protocol used at Aarhus University Hospital
- You should not be excluded by not meeting the study’s basic inclusion rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the body processes a steroid medicine called dexamethasone in children with ALL, and how it might affect bone strength.
This study looks at how the immune system reacts to a chemotherapy drug called PEG asparaginase in children and young adults. Understanding this could help improve treatment for leukemia by managing or reducing allergic reactions.
This research study examines how your immune system (specifically T cells) reacts to asparaginase, a drug used to treat acute lymphoblastic leukemia. By understanding these reactions, doctors hope to predict and prevent allergic or sensitivity problems during your cancer treatment.
This trial tests a treatment plan for people with a certain type of acute lymphoblastic leukemia (ALL) called B-lineage ALL. It aims to see how well the treatment works and how safe it is.
This study looks at how the adrenal glands recover after children with leukemia or lymphoma are treated with steroids. The goal is to see how common adrenal suppression is and to help doctors monitor this safely.
This study looks at how a chemotherapy drug called calaspargase pegol affects blood clotting in children and young adults with leukemia. It will help doctors understand if changes in clotting are common and safe.
Hear when a new Precursor Cell Lymphoblastic Leukemia-Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.